论文部分内容阅读
目的:探讨益肝康抗肝纤维化作用机制、配伍意义。方法:分别制备益肝康及其拆方——丹参小复方纯化浸膏、正常大鼠及肝纤维化大鼠药物血清,温育体外培养的HSC,RT-PCR和Western blot技术检测TGF-β1 mRNA及蛋白表达,RT-PCR和流式细胞技术检测TβR-I mRNA及蛋白表达。结果:益肝康及丹参小复方纯化浸膏、正常大鼠和肝纤维化大鼠药物血清均可以抑制TGF-β1与受体TβR-I基因及蛋白表达,益肝康作用优于小复方,肝纤维化大鼠药物血清作用优于正常大鼠药物血清。结论:益肝康及丹参小复方抗肝纤维化的主要机制之一是抑制TGF-β1与TβR-I基因和蛋白表达,益肝康全方更具配伍意义,肝纤维化大鼠药物血清与正常大鼠药物血清药效学不同。
Objective: To explore the mechanism and compatibility of Yigan Kang in treating liver fibrosis. Methods: The serum of Yigankang and its decomposed prescriptions were prepared respectively. The drug serum was extracted from Salvia miltiorrhiza compound extract, normal rats and hepatic fibrosis rats. HSCs were incubated in vitro and TGF-β1 was detected by RT-PCR and Western blot. mRNA and protein expression, RT-PCR and flow cytometry were used to detect TβR-I mRNA and protein expression. Results: The serum of Yigankang and Salvia miltiorrhiza compound extract, normal rats and hepatic fibrosis rats could inhibit the expression of TGF-β1 and TβR-I receptor and protein, and the effect of Yigankang was better than that of Xiaogan compound. The hepatic fibrosis rat drug serum than normal rat drug serum. Conclusion: One of the main mechanisms of Yigankang and Salvia miltiorrhiza compound anti-fibrosis is to inhibit the expression of TGF-β1 and TβR-I genes and protein, Yigankangquanfang is more compatible, and the drug serum and normal size of liver fibrosis rats Rat drug serum has different pharmacodynamics.